Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
γδ T cells provide a safe and effective platform laying the foundation for allogeneic 'off-the-shelf' cell therapies for cancer. With the extensive experience in TCR-T therapy, Creative Biolabs provides one-stop αβ TCR-engineered γδ T development services for our worldwide customers.
TCR-engineered therapy is a promising and continually evolving form of cancer treatment. TCR-T immunotherapy technique activates the host's immune system through efficient interaction with MHC, especially class II molecules. γδ T cells can be safely applied in the allogeneic setting and exhibit natural anti-tumor reactivity and are suitable for cell therapy projects. γδ T cells transduced with αβ TCRs retain the functionality of their original TCR and respond to stimuli transferred via either TCR with rapid, γδ-like kinetics. Thus, transferring αβ TCRs into γδ T cells generate potent effector T cells is a promising therapeutic strategy.
Fig.1 αβ TCR engineered γδ T cells and their functions. (Creative Biolabs)
Transferring a new αβ TCR gene construct into an αβ T cells runs the risk of TCR chain mispairing unless the endogenous α and β chains are suppressed. Concurrent expression of endogenous and transgenic TCRs in one and the same T cell may impair efficacy and cause safety problems owing to mispairings. Given the inherent disadvantage of αβ TCR transfer to other αβ T cells, γδ T cells are useful as an alternative population for TCR transfer because γδ TCRs are not capable of forming dimers with αβ TCRs. Several studies have show αβ TCR engineered γδ T cells exerted high levels of antigen-specific cytotoxicity and produced IFN-γ and IL-4, particularly in the presence of the relevant coreceptor. Compared with conventional TCR-T cells, αβ TCR-γδ T cells acquire a superior proliferation potential, tumor antigen specificity, while maintaining their intrinsic homing ability and avoiding graft versus host reaction (GvHD).
Fig.2 Transduction of γδ T cells with an αβ TCR provides a means of circumventing the potential mispairing problem. (Mirzaei, 2016)
Creative Biolabs provides one-stop αβ TCR-engineered γδ T cell development services to meet our clients' academic or clinical purposes. We transfer the αβ TCR gene into a vector. Moreover, because most γδ T cells do not express CD4 and CD8, we subsequently transferred these coreceptors into γδ T cells. Following the proliferation of αβ TCR-γδ T cells, we carry out functional validation. Since αβ TCR-γδ T cells are stimulated either through αβ TCR or γδ TCR, it is necessary to assess αβ TCR-γδ T cells specific response.
Creative Biolabs supports your research at every pre-clinical stage of the drug development and cell therapies. Our experienced Ph.D. level scientists can offer the solutions according to your budget, timeline and specific requirements. Please feel free to contact us to learn more.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
